Changing Policies for Kidney Care

More than 1 in 7 American adults has chronic kidney disease (CKD), with the majority of those affected unaware of it. CKD is associated with heart disease, stroke, kidney failure and early death. Chronic kidney care for patients who have… Read »

Focusing on NASH

Non-alcoholic fatty liver disease (NAFLD), the build-up of fat in the liver that is not caused by alcohol, affects almost 100 million people in the United States alone. With no drug therapies available for the condition, treatment has focused mostly… Read »

Gilead and Galapagos

With Gilead Sciences’ hepatitis C sales revenues from Solvaldi and Harvoni fading and lower than expected Yescarta sales, the company has been looking for new products to bolster its pipeline. In mid-July, Gilead addressed some of this need by deepening… Read »

Zolgensma Launch “On Track,” but Significant Challenges Remain

On July 18, Novartis told analysts its Zolgensma launch was “on track.” Despite the gene therapy’s $2.1 million price tag, the company states the launch is “one of the most successful launches from an access standpoint in rare diseases.” Novartis… Read »

The Rise of the Chief Digital Officer in Pharma Companies

Chief Digital Officer (CDO) is the latest title to become a standard within the pharmaceutical company C-suite, with Takeda, Bayer, GlaxoSmithKline, Novartis, Merck, Sanofi and others all making such appointments in recent years. As we’ve written before, this addition to… Read »

Applying Precision Medicine to Neuropsychiatric Disorders

Cancers were once looked upon as specific diseases, often defined by their tissue of origin, and drug treatments primarily aimed to kill rapidly growing tumor cells before harming slower growing normal ones. The result was often limited drug efficacy, accompanied… Read »

New Excitement About Antibody-Drug Conjugates in Cancer

The ability to target malignant cells without damage to surrounding healthy ones has been a long-sought goal in cancer drug development. Antibody-drug conjugates (ADCs) have been investigated as one such solution aimed at delivering more targeted therapies. ADCs — an… Read »

Blockchain and Pharmaceutical Supply Chain Security

Blockchain is a method to securely store digital information and create an accurate, verifiable, distributed record of individual transactions that is confidential, traceable and virtually uneditable. The first practical use of blockchain technology enabled bitcoin and other cryptocurrency transactions. Today,… Read »

AI Aiding Earlier, More Accurate Cancer Screening

Recent research clearly illustrates the potential that artificial intelligence (AI) and deep learning systems offer for improving the detection and diagnosis of cancer, whether from radiological images or tissue analysis. While further clinical validation of such systems is needed before… Read »

Real World Evidence Replacing Some Clinical Trials?

Pharmaceutical companies have long used real-world data on drug performance to help justify their pricing decisions to payers. But now such real-world evidence (RWE), gathered from electronic medical records (EMRs), national patient registries and other patient databases, is increasingly being… Read »

1 2 3 4 5 19